OBJECTIVE: CD34(+) cells, present within the bone marrow, have previously been shown to possess pancreatic endocrine potential. Based on this observation, we explored the capacity of CD34(+) cells derived in culture from the differentiation of human embryonic stem cells (hESC), for their in vivo pancreatic endocrine capacity. MATERIALS AND METHODS: Sheep were transplanted with hESC-derived CD34(+) cells, as well as nonsorted differentiated cultures. Transplantations were carried out with in utero intraperitoneal injections prior to development of the immune system in the fetus so that tolerance toward foreign antigens was acquired during gestation and persisted in the adult. RESULTS: All cell populations that were tested demonstrated human cellular activity and long-term presence up to 5 years. However, the in vivo beta-cell-like activity achieved from the transplantation of the sorted CD34(+) cell population was not augmented by transplanting the entire cell population from which the CD34(+) cells were isolated. Human DNA and insulin messenger RNA were detected in sheep pancreases. An average of 1.51 ng/mL human C-peptide was detected in serum from eight animals transplanted with differentiated cell populations and assayed up to 55 months posttransplantation. Transplantation of as few as 23,500 cells resulted in long-term sustainable beta-cell-like activity. Teratomas were absent in the transplanted animals. CONCLUSION: Our data suggest that hESC-derived CD34(+) cells have a potential for long-term in vivo endocrine cellular activity that could prove useful in regenerative medicine. Because the same cell population has previously been shown to contain hematopoietic potential, it could be used for the induction of immunological tolerance and bone marrow chimerism prior to cellular therapy for diabetes. Copyright 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
OBJECTIVE:CD34(+) cells, present within the bone marrow, have previously been shown to possess pancreatic endocrine potential. Based on this observation, we explored the capacity of CD34(+) cells derived in culture from the differentiation of human embryonic stem cells (hESC), for their in vivo pancreatic endocrine capacity. MATERIALS AND METHODS:Sheep were transplanted with hESC-derived CD34(+) cells, as well as nonsorted differentiated cultures. Transplantations were carried out with in utero intraperitoneal injections prior to development of the immune system in the fetus so that tolerance toward foreign antigens was acquired during gestation and persisted in the adult. RESULTS: All cell populations that were tested demonstrated human cellular activity and long-term presence up to 5 years. However, the in vivo beta-cell-like activity achieved from the transplantation of the sorted CD34(+) cell population was not augmented by transplanting the entire cell population from which the CD34(+) cells were isolated. Human DNA and insulin messenger RNA were detected in sheep pancreases. An average of 1.51 ng/mL humanC-peptide was detected in serum from eight animals transplanted with differentiated cell populations and assayed up to 55 months posttransplantation. Transplantation of as few as 23,500 cells resulted in long-term sustainable beta-cell-like activity. Teratomas were absent in the transplanted animals. CONCLUSION: Our data suggest that hESC-derived CD34(+) cells have a potential for long-term in vivo endocrine cellular activity that could prove useful in regenerative medicine. Because the same cell population has previously been shown to contain hematopoietic potential, it could be used for the induction of immunological tolerance and bone marrow chimerism prior to cellular therapy for diabetes. Copyright 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
Authors: David Hess; Li Li; Matthew Martin; Seiji Sakano; David Hill; Brenda Strutt; Sandra Thyssen; Douglas A Gray; Mickie Bhatia Journal: Nat Biotechnol Date: 2003-06-22 Impact factor: 54.908
Authors: J B Choi; H Uchino; K Azuma; N Iwashita; Y Tanaka; H Mochizuki; M Migita; T Shimada; R Kawamori; H Watada Journal: Diabetologia Date: 2003-07-26 Impact factor: 10.122
Authors: Graça Almeida-Porada; Christopher D Porada; Jason Chamberlain; Ali Torabi; Esmail D Zanjani Journal: Blood Date: 2004-07-01 Impact factor: 22.113
Authors: Junying Yu; Kejin Hu; Kim Smuga-Otto; Shulan Tian; Ron Stewart; Igor I Slukvin; James A Thomson Journal: Science Date: 2009-03-26 Impact factor: 47.728
Authors: Andreas Lechner; Yong-Guang Yang; Robyn A Blacken; Lan Wang; Anna L Nolan; Joel F Habener Journal: Diabetes Date: 2004-03 Impact factor: 9.461
Authors: Claudia Merkwitz; Tiina Pessa-Morikawa; Paul Lochhead; Gessner Reinhard; Michiharu Sakurai; Antti Iivanainen; Albert M Ricken Journal: Histochem Cell Biol Date: 2011-01-04 Impact factor: 4.304
Authors: A Daisy Goodrich; Nicole M Varain; Christine M Jeanblanc; Donna M Colon; Jaehyup Kim; Esmail D Zanjani; Peiman Hematti Journal: Cytotherapy Date: 2014-09 Impact factor: 5.414
Authors: Jinming Li; Zhi C Feng; Frances S-H Yeung; Melanie R-M Wong; Amanda Oakie; George F Fellows; Cynthia G Goodyer; David A Hess; Rennian Wang Journal: Diabetologia Date: 2013-12-28 Impact factor: 10.122